Solana Beach, Calif., July 22, 2026
Artelo Biosciences announced the publication of a peer-reviewed review article in the British Journal of Clinical Pharmacology analyzing data from more than 50 clinical and pharmacokinetic studies evaluating low-dose cannabidiol (CBD) products commonly available without prescription. The comprehensive analysis concluded that all non-prescription CBD products examined failed to achieve drug exposure levels associated with therapeutic efficacy at the doses studied. Researchers found that the plasma concentrations produced by these oral CBD formulations were five to one hundred times lower than those achieved with approved prescription CBD therapies used to treat epilepsy, suggesting that poor bioavailability rather than CBD itself may explain the limited clinical benefits observed. The findings reinforce the scientific rationale behind Artelo’s proprietary ART12.11 CBD cocrystal formulation, which has been designed to improve CBD bioavailability and potentially deliver meaningful therapeutic effects across multiple disease indications.
Review Highlights Limited Effectiveness of Low-Dose CBD Products
The publication evaluated efficacy, pharmacokinetics, and safety data from randomized controlled trials and pharmacokinetic studies involving both healthy volunteers and patient populations receiving low-dose CBD at 2.5 mg/kg or less, or up to 175 mg per day, which reflects the dosage range commonly found in retail products. According to the analysis, these doses produced little to no measurable biological activity or therapeutic benefit despite generally favorable safety profiles. Researchers also identified important drug-drug interactions involving commonly used medications such as Δ9-tetrahydrocannabinol (THC), amitriptyline, and hydromorphone, highlighting potential safety considerations when non-prescription CBD products are used alongside other therapies. The review concludes that inadequate systemic drug exposure, largely resulting from poor formulation and limited absorption, represents a major obstacle preventing many commercially available CBD products from achieving clinically meaningful outcomes.
ART12.11 Designed to Improve CBD Bioavailability
Building on these findings, Artelo Biosciences emphasized the potential advantages of its proprietary ART12.11 formulation, a cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) engineered to improve the pharmacokinetic performance of CBD. Previous preclinical studies conducted by the company demonstrated that oral administration of ART12.11 produced higher plasma concentrations of CBD and its primary metabolite compared with conventional CBD formulations, potentially enabling improved therapeutic efficacy. Researchers believe enhanced bioavailability, combined with a commercially scalable tablet formulation capable of delivering consistent and adjustable dosing, could overcome many of the limitations identified in existing over-the-counter CBD products. The company also noted that the composition is protected by a U.S. patent extending through December 2038, with intellectual property rights granted or validated in more than 20 additional countries.t.
Advertisement
Publication Supports Continued Clinical Development Strategy
According to Artelo Biosciences, the review strengthens the case for evidence-based pharmaceutical development of CBD therapies rather than reliance on widely available low-dose commercial products. While the reviewed CBD formulations generally demonstrated favorable tolerability and no serious safety concerns, researchers emphasized that safety alone provides limited clinical value when adequate therapeutic benefit cannot be achieved. The company believes ART12.11’s enhanced pharmacokinetic profile could enable clinicians to better evaluate the true therapeutic potential of CBD while carefully managing known drug interaction risks. Artelo plans to report additional preclinical research results for ART12.11 in the near future before advancing the investigational formulation into clinical development. With a diversified pipeline targeting cancer, pain, anxiety, dermatological diseases, inflammation, and neurological disorders, the company continues to focus on developing optimized cannabinoid-based therapies supported by rigorous scientific and regulatory research.
Source: Artelo Biosciences press release
